Viking Therapeutics
A clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and endocrine disorders.
Launch date
Employees
Market cap
€6.3b
Enterprise valuation
€5.5b (Public information from Sep 2024)
Share price
$70.47 VKTX
San Diego California (HQ)
Authorizing premium user...